Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults

To assess the acute effects of 0.7 mg intranasal glucagon (ING) vs intranasal placebo (INP) on food intake and resting energy expenditure (REE).

• Publication year

  2019

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2019-03-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.13661PMID 30740846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

  2018cited by this paper
• Evaluation of the specific effects of intranasal glucagon on glucose production and lipid concentration in healthy men during a pancreatic clamp

  2018influential reference
• MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.

  2018cited by this paper
• Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

  2018cited by this paper
• The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.

  2017cited by this paper
• Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice

  2017cited by this paper
• Changes in Energy Expenditure with Weight Gain and Weight Loss in Humans

  2016cited by this paper
• Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance

  2016cited by this paper
• Differential Effects of Bariatric Surgery Versus Exercise on Excessive Visceral Fat Deposits

  2016cited by this paper
• Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.

  2016cited by this paper
• Hypothalamic CaMKKβ mediates glucagon anorectic effect and its diet-induced resistance

  2015cited by this paper
• Glucagon signalling in the dorsal vagal complex is sufficient and necessary for high‐protein feeding to regulate glucose homeostasis in vivo

  2015cited by this paper
• Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

  2015cited by this paper
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

  2015cited by this paper
• Glucagon increases energy expenditure independently of brown adipose tissue activation in humans

  2015cited by this paper
• Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study

  2015cited by this paper
• Intranasal Insulin Suppresses Endogenous Glucose Production in Humans Compared With Placebo in the Presence of Similar Venous Insulin Concentrations

  2014influential reference
• Long-term follow-up after bariatric surgery: a systematic review.

  2014cited by this paper
• The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012.

  2014cited by this paper
• Glucagon is essential for adaptive thermogenesis in brown adipose tissue.

  2014cited by this paper
• Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake

  2014cited by this paper
• Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

  2013cited by this paper
• Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

  2013cited by this paper
• Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

  2013cited by this paper
• Hypothalamic glucagon signaling inhibits hepatic glucose production

  2013cited by this paper
• Prevalence of alcohol use disorders before and after bariatric surgery.

  2012cited by this paper
• Acute sleep deprivation reduces energy expenditure in healthy men.

  2011cited by this paper
• Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity

  2010cited by this paper
• The metabolic actions of glucagon revisited

  2010cited by this paper
• Risk of suicide after long-term follow-up from bariatric surgery.

  2010cited by this paper
• Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2010cited by this paper
• Characteristics of compounds that cross the blood-brain barrier

  2009cited by this paper
• Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin.

  2008cited by this paper
• Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia

  2006cited by this paper
• Gonadal hormones determine sensitivity to central leptin and insulin.

  2006cited by this paper
• Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status.

  2006cited by this paper
• Intranasal insulin reduces body fat in men but not in women.

  2004cited by this paper
• Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects

  2004cited by this paper
• Differential sensitivity to central leptin and insulin in male and female rats.

  2003cited by this paper
• Sniffing neuropeptides: a transnasal approach to the human brain

  2002cited by this paper
• The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

  2000cited by this paper
• Evidence that glucagon stimulates insulin secretion through its own receptor in rats

  1995cited by this paper
• In vivo regulation of lipolysis in humans.

  1994cited by this paper
• Bariatric Surgery vs Conventional Dieting in the Morbidly Obese

  1994cited by this paper
• Glucagon and the paraventricular hypothalamus: modulation of energy balance.

  1993cited by this paper
• Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men.

  1992cited by this paper
• Importance of glucagon as a determinant of resting metabolic rate and glucose-induced thermogenesis in obese women.

  1991cited by this paper
• Weight loss leads to a marked decrease in nonresting energy expenditure in ambulatory human subjects.

  1988cited by this paper
• Importance of glucagon in the control of futile cycling as studied in alloxan-diabetic dogs

  1987cited by this paper
• Effects of selective insulin or glucagon deficiency on glucose turnover.

  1979cited by this paper
• Regulation of Insulin Release by Pancreatic Glucagon

  1970cited by this paper
• Glucagon Potentiation of Insulin Secretion by the Perfused Rat Pancreas

  1970cited by this paper
• Characteristics

  1895cited by this paper

• Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions

  2025cites this paper
• Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs

  2025cites this paper
• Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes

  2024cites this paper
• Comparative Effect of Insulin Resistance Reduction and Hormonal Alterations on Type 2 Diabetes Remission After Bariatric Surgery

  2024cites this paper
• Emerging Pharmacotherapies for Obesity: A Systematic Review.

  2024cites this paper
• Glucagon and Energy Expenditure; Revisiting amino acid metabolism and implications for weight loss therapy.

  2023cites this paper
• The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis

  2022influential citation
• Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?

  2022cites this paper
• Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial

  2021cites this paper
• Fasting Glucagon Level in Type 2 Diabetes and Impaired Glucose Tolerance and Its Association With Diabetes-Associated Clinical Parameters: A Study From Karachi, Pakistan

  2021cites this paper
• Multi-organ coordination of lipoprotein secretion by hormones, nutrients and neural networks.

  2021cites this paper
• Association of Glucagon With Obesity, Glycemic Control and Renal Function in Adults With Type 2 Diabetes Mellitus.

  2020cites this paper
• Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia

  2019cites this paper
• Glucagon Regulation of Energy Expenditure

  2019cites this paper